Hypothesis-Generating Brief: Plasma proteomic age clocks

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add a substantive Key Findings section that reports the actual directional signal, effect sizes, and outcome-class patterns from the retained bundle (e.g., the consistent associations between proteomic age acceleration and all-cause mortality, multimorbidity, and organ-specific disease onset reported by Argentieri 2024, Kuo 2024, Wang 2025, Oh 2025) and reconcile these against the coded null/unclear tally.
2. Recompute or explicitly justify the directional coding: the abstract claims 58/60 sources are null/no signal while the bundle contains multiple large cohort studies (UK Biobank n>40,000) with clear positive associations between proteomic age acceleration and adverse outcomes. Either the coding is incorrect or the bundle does not match the coded corpus; this must be reconciled before acceptance.
3. Re-screen source inclusion: exclude or explicitly relabel sources that are not about proteomic age clocks per se but rather disease-specific plasma proteomics biomarker discovery (e.g., concussion, RA, psoriasis, laminitis, pre-eclampsia); these do not answer the research question as posed.
4. Quantify the within-class synthesis that the Methods promise (e.g., range of reported HRs for mortality per SD of proteomic age acceleration, cross-cohort replication rates, organ-aging hazard ratios) so the Evidence Landscape table is paired with at least one integrative paragraph per major outcome class.
5. Tighten the Gaps section to specify which endpoint, which population, and which comparator each next-step study should target.
6. Remove the duplicate 'Outcome-class note' that appears verbatim in both Evidence Landscape and Key Findings.

Major issues

• The Key Findings section is effectively empty of substantive content beyond restating the outcome-class note and reporting template — it duplicates the Evidence Landscape framing without extracting or summarizing any actual directional or quantitative findings from the 60-source corpus.
• The Synthesis approach claims 'Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates,' but no pooling, meta-statistic, or within-class integration is actually reported anywhere in the manuscript; the Evidence Landscape is a tally table, not a synthesis.
• The source bundle contains multiple direct primary studies on plasma proteomic age clocks (Argentieri 2024, Kuo 2024, Wang 2025, Oh 2025, Ma 2025, Zhang 2025, Lehallier-style PAC work) that report concrete directional findings (mortality HRs, disease associations, proteomic age acceleration correlations), yet the manuscript codes essentially all retained sources as null or no extracted directional signal — this discrepancy is not reconciled and raises questions about whether extraction captured the bundle's actual signal.

Minor issues

• Several bundle entries (e.g., Vadaq 2022, Manousopoulou 2020, Huang 2025, Gonzales 2020, Pooja 2021, He 2025, Tachino 2024, Steelman 2012) are not primarily about plasma proteomic AGE CLOCKS but about plasma proteomics for biomarker discovery in specific diseases; their inclusion under a 'plasma proteomic age clocks' synthesis question is questionable and should be re-screened or annotated.
• The Search Summary states RCT-filtered queries were run but the admission funnel and source bundle contain no RCTs, and the manuscript does not report this as a limitation.
• The Conclusion is repetitive and meta-methodological; it could be condensed to one paragraph that states the bounded verdict and then anchors to specific outcome-class signals.
• Immune and Inflammation outcome class appears to have two sub-blocks (7 sources and 5 sources) without clear integration, and the Longevity outcome class totals (n=4) are inconsistently described across the table and narrative.
• Gaps section references 'immune' without naming specific endpoints, populations, or comparators needed to make the gap actionable.

Reviewer note

This rapid evidence synthesis on plasma proteomic age clocks is honest about the limited directness of its corpus (1/60 direct clinical sources) and appropriately refuses to make causal or policy claims. That is a genuine strength. However, the manuscript has a critical structural weakness: the Key Findings section contains no actual findings, the Evidence Landscape is a pure tally of null-coded sources, and the synthesis approach promises quantitative pooling and within-class integration that never materialize. Worse, the abstract's claim that 58/60 sources are null/no-extracted-signal is difficult to reconcile with the source bundle, which includes multiple large UK Biobank studies (Argentieri 2024 n=45,441; Kuo 2024 n=53,021; Wang 2025 n=43,616; Oh 2025 n=44,498; Ma 2025 n=51,904) reporting clear positive associations between proteomic age acceleration and mortality, multimorbidity, and organ-specific disease incidence. If those signals are genuinely 'no extracted directional signal,' the extraction pipeline under-captured the bundle; if the bundle does not match the coded corpus, the synthesis cannot be audited. Either way, this must be reconciled. The bundle also contains many disease-specific plasma proteomics studies (HIV, malaria, concussion, equine laminitis, psoriasis) that are not about age clocks and should be re-screened. With a genuine within-class synthesis that reports actual effect estimates from the core age-clock studies, a clearer justification of the inclusion set, and reconciliation of the null-coding with the bundle's apparent positive signals, this could become a competent and properly bounded synthesis. In its current form, it is mostly a template scaffold with honest framing but no substantive findings. Verdict: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis